vTv Therapeutics Inc (VTVT) USD0.01 A
Sell:$6.01Buy:$22.72
$0.46
(3.06%)
- This stock can be held in a
Stocks and Shares ISA$0.46
(3.06%)$0.46
(3.06%)Company Information
About this company
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.
Key people
Key facts
- EPICVTVT
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS9183852048
- Market cap$43.83m
- Employees16
- Shares in issue2.61m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.